AR125373A1 - POLYCLONAL ANTIBODIES AGAINST SARS-CoV-2 AND ITS APPLICATIONS - Google Patents
POLYCLONAL ANTIBODIES AGAINST SARS-CoV-2 AND ITS APPLICATIONSInfo
- Publication number
- AR125373A1 AR125373A1 ARP220100990A ARP220100990A AR125373A1 AR 125373 A1 AR125373 A1 AR 125373A1 AR P220100990 A ARP220100990 A AR P220100990A AR P220100990 A ARP220100990 A AR P220100990A AR 125373 A1 AR125373 A1 AR 125373A1
- Authority
- AR
- Argentina
- Prior art keywords
- variants
- equine
- plasma
- spike protein
- cov
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title abstract 3
- 241000283073 Equus caballus Species 0.000 abstract 7
- 229940096437 Protein S Drugs 0.000 abstract 5
- 101710198474 Spike protein Proteins 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 4
- 102000005593 Endopeptidases Human genes 0.000 abstract 3
- 108010059378 Endopeptidases Proteins 0.000 abstract 3
- 241000315672 SARS coronavirus Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 239000000706 filtrate Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000001728 nano-filtration Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación divulga un proceso para obtener fragmentos de anticuerpos policlonales F(ab)₂ contra la proteína espicular o variantes de esta y del coronavirus del síndrome respiratorio agudo grave de tipo 2 (SARS-CoV-2) a partir de equinos hiperinmunizados. La presente divulgación también divulga un fragmento de anticuerpo policlonal F(ab)₂ contra la proteína espicular o variantes del SARS-CoV-2. También se divulga en el presente documento una composición que comprende los fragmentos de anticuerpos policlonales F(ab)₂. Los fragmentos de anticuerpos policlonales F(ab)₂ de la presente divulgación presentan una mejor actividad neutralizante contra diferentes variantes de RBD del SARS-CoV-2 y pueden utilizarse para el tratamiento de la enfermedad del coronavirus en un sujeto. Reivindicación 1: Un proceso para obtener fragmentos F(ab)₂ de anticuerpos policlonales contra la proteína espicular o las variantes de esta del síndrome respiratorio agudo grave coronavirus 2 caracterizado porque comprende: (a) obtener una formulación de antígenos que comprende la proteína espicular o variantes de esta del síndrome respiratorio agudo grave coronavirus 2 y al menos un adyuvante, donde la proteína espicular o las variantes de estas es al menos 200 residuos de aminoácidos contiguos de la SEQ ID Nº 1; (b) inmunizar un equino con la formulación de antígeno; (c) inmunizar el equino con uno o más dosis de refuerzo durante un periodo de tiempo en el intervalo de 21 a 30 días; (d) extraer sangre del equino después de 10 a 14 días posteriores a cada dosis de refuerzo y asilar el plasma de la sangre; (e) tratar el plasma con solución salina para obtener un plasma tratado; (f) digerir el plasma tratado del paso (e) con una endopeptidasa para obtener el plasma digerido con endopeptidasa; (g) precipitar el plasma digerido con la endopeptidasa del paso (f) con ácido octanoico para obtener una mezcla de antisuero de equino; (h) centrifugar y filtrar la mezcla de antisuero de equino mediante diafiltración; (i) purificar la mezcla de antisuero de equino mediante cromatografía para obtener un filtrado; y (j) purificar el filtrado del paso (i) mediante nanofiltración para obtener fragmentos F(ab)₂ de anticuerpos policlonales contra el coronavirus del síndrome respiratorio agudo grave de tipo 2.This disclosure discloses a process for obtaining F(ab)₂ polyclonal antibody fragments against the spike protein or variants thereof and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) from hyperimmunized equines. The present disclosure also discloses a polyclonal F(ab)₂ antibody fragment against the spike protein or variants of SARS-CoV-2. Also disclosed herein is a composition comprising the F(ab)₂ polyclonal antibody fragments. The F(ab)₂ polyclonal antibody fragments of the present disclosure exhibit enhanced neutralizing activity against different RBD variants of SARS-CoV-2 and can be used for treatment of coronavirus disease in a subject. Claim 1: A process for obtaining F(ab)₂ fragments of polyclonal antibodies against the spike protein or its variants of severe acute respiratory syndrome coronavirus 2 characterized in that it comprises: (a) obtaining an antigen formulation comprising the spike protein or variants thereof of severe acute respiratory syndrome coronavirus 2 and at least one adjuvant, wherein the spike protein or variants thereof is at least 200 contiguous amino acid residues of SEQ ID No. 1; (b) immunizing an equine with the antigen formulation; (c) immunizing the equine with one or more booster doses for a period of time in the range of 21 to 30 days; (d) drawing blood from the equine 10 to 14 days after each booster dose and isolating the plasma from the blood; (e) treating the plasma with saline to obtain a treated plasma; (f) digesting the treated plasma from step (e) with an endopeptidase to obtain the endopeptidase digested plasma; (g) precipitating the endopeptidase digested plasma from step (f) with octanoic acid to obtain a pooled equine antiserum; (h) centrifuging and filtering the equine antiserum mixture by diafiltration; (i) purifying the equine antiserum mixture by chromatography to obtain a filtrate; and (j) purifying the filtrate from step (i) by nanofiltration to obtain F(ab)₂ fragments of polyclonal antibodies against severe acute respiratory syndrome coronavirus type 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202121018115 | 2021-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125373A1 true AR125373A1 (en) | 2023-07-12 |
Family
ID=83722769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100990A AR125373A1 (en) | 2021-04-19 | 2022-04-18 | POLYCLONAL ANTIBODIES AGAINST SARS-CoV-2 AND ITS APPLICATIONS |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR125373A1 (en) |
| WO (1) | WO2022224271A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117379399A (en) * | 2023-06-27 | 2024-01-12 | 江生(深圳)生物技术研发中心有限公司 | Horse-derived immunoglobulin inhalation liquid formulation and preparation and use methods thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2568838A1 (en) * | 2004-06-04 | 2005-12-15 | Institut Pasteur | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
| FR2899112B1 (en) * | 2006-03-31 | 2010-09-03 | Lab Francais Du Fractionnement | CONCENTRATE OF IMMUNOGLOBULINS AND F (AB) '2 AND / OR FAB FRAGMENTS SPECIFIC OF ARBOVIRUS AS A MEDICAMENT. |
| US10953089B1 (en) * | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| AU2020340881A1 (en) * | 2020-04-02 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
| US10906944B2 (en) * | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
| CN112010963B (en) * | 2020-07-20 | 2022-05-20 | 江苏集萃医学免疫技术研究所有限公司 | SARS-COV-2 antibody and use thereof |
| KR102233689B1 (en) * | 2020-11-26 | 2021-03-30 | 재단법인 오송첨단의료산업진흥재단 | Antibodies specifically binding to receptor-binding domain of SARS-CoV-2 spike protein and use thereof |
-
2022
- 2022-04-18 WO PCT/IN2022/050371 patent/WO2022224271A1/en active Application Filing
- 2022-04-18 AR ARP220100990A patent/AR125373A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022224271A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2951622C (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| Brady | Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens | |
| ATE330631T1 (en) | ANTIBODIES FRAGMENTS FOR THE LOCAL TREATMENT OF EYE DISEASES | |
| AR125373A1 (en) | POLYCLONAL ANTIBODIES AGAINST SARS-CoV-2 AND ITS APPLICATIONS | |
| CO6640239A2 (en) | Process for preparing an immunoglobulin composition | |
| EA017549B1 (en) | Stable liquid antibody formulations against anti-rabies virus | |
| AR078734A1 (en) | COMPOSITIONS, METHODS FOR TREATMENT, AND DIAGNOSIS OF DISORDERS RELATED TO AUTOIMMUNITY AND METHODS TO PREPARE SUCH COMPOSITIONS | |
| JP2006347922A (en) | Antibody enzyme against hemagglutinin of influenza virus | |
| AU2010319047A1 (en) | Therapeutic agent for psoriasis or atopic dermatitis | |
| EA008104B1 (en) | Medical agent and method for treating erectile dysfunction | |
| TWI481411B (en) | Dengue vaccine, medicinal composition comprising the same, nucleotide sequence, and method for manufacturing the medical composition | |
| RU2017100658A (en) | THERAPEUTIC AGAINST Helicobacter | |
| BR112020011240A2 (en) | use of a fxiia inhibitor in the treatment of renal fibrosis and / or chronic kidney disease | |
| Shelke et al. | Equine rabies immunoglobulin: A review | |
| Kalil et al. | Production and utilization of snake antivenoms in South America | |
| Squaiella-Baptistão et al. | Quality of horse F (ab′) 2 antitoxins and antirabies immunoglobulins: protein content and anticomplementary activity | |
| RU2020117362A (en) | METHODS FOR TREATMENT OF TENDINOPATHY WITH INTERLEUKIN-17 (IL-17) ANTAGONISTS | |
| Lovreček et al. | A century of antivenom | |
| CN1947727A (en) | Anti-echidnotoxin blood serum and its preparing method | |
| CN1250572C (en) | Anti-body capable to selectively detect prion PrPsc isoforms | |
| JPH02504512A (en) | Antibodies against angiogenin: immunotherapeutic agents | |
| Tizard | Passive immunization | |
| JPH06100591A (en) | Peptide, antibody derived therefrom and anti-newcastle disease agent containing the same antibody | |
| US606042A (en) | On-the-main | |
| RU2647374C1 (en) | Method for prevention of anaphylactic shock at heterological serums introduction |